Altimmune (ALT) announced that it has enrolled the first subject in the RECLAIM Phase 2 trial evaluating the efficacy and safety of pemvidutide in subjects with Alcohol Use Disorder, AUD. Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of metabolic dysfunction-associated steatohepatitis, obesity, AUD and alcohol liver disease. IMPACT, a Phase 2b trial of pemvidutide in MASH, is expected to read out topline data in the second quarter of 2025, and a Phase 2 trial of pemvidutide in ALD is expected to initiate enrollment in the third quarter of 2025. “There are compelling data that GLP-1 agents may reduce the craving for alcohol in addition to reducing food consumption,” said Scott Harris, M.D., Chief Medical Officer of Altimmune.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALT:
- Altimmune’s Earnings Call: NASH Trial & Financial Moves
- Altimmune’s Strategic Advancements and Promising Clinical Trials Justify Buy Rating
- Altimmune’s 2025 Q1 Results Highlight Clinical Progress
- Morning Movers: UnitedHealth sinks following CEO exit and outlook suspension
- Altimmune secures up to $100M in credit facility